Latest Feature

Medicare: Medical device companies paid out $200m to physicians last year

Medical device companies' aggregate spend on payment and other gifts to physicians was at least $200 million last year, according to the U.S. Health & Human Services Dept., but critics (and the agency itself) flag widespread problems with the Open Payments database.

Checking on Orange County's medtech climate with OCTANe's Matthew Jenusaitis

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to MassDevice.com about OCTANe's 2014 Medical Device Investor Forum.

What's behind the slump in early-stage medtech investment?

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

HART CEO David Green on the transformative potential for regenerative medicine

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

U.S. Patent Office denies Medtronic request in Endotach stent case

October 22, 2014 by Val Kennedy

The U.S. Patent & Trademark Office denies Medtronic's request for inter partes review of a disputed patent in its ongoing case against Endotach.

U.S. Patent Office denies Medtronic request in Endotach stent case

MassDevice.com +3 | The top 3 medtech stories for October 22, 2014

October 22, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

EQT frontrunner for Siemens hearing-aids business: sources

October 22, 2014 by MassDevice

Siemens is in advanced talks to sell its hearing-aids business to private equity shop EQT, unnamed sources tell Reuters.

EQT frontrunner for Siemens hearing-aids business: sources

Sorin drops $20m on stake in Respicardia

October 22, 2014 by Alexander Soule

Sorin Group drops $20 million on a stake in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

Sorin drops $20m on stake in Respicardia

Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

Jury deliberations begin in first trial over DePuy's Pinnacle hips

October 22, 2014 by MassDevice

A jury begins deliberations in the 1st trial over DePuy Orthopaedics' Pinnacle metal-on-metal hip implant.

Jury deliberations begin in first trial over DePuy's Pinnacle hips

U.S. government probes medical devices for possible cyber flaws

October 22, 2014 by MassDevice

The U.S. Homeland Security Dept. is investigating reports of cybersecurity flaws in medical devices including some made by Medtronic, St. Jude Medical and Hospira.

YYmeta

(Reuters) - The U.S. Homeland Security Dept. is investigating about 2 dozen cases of suspected cybersecurity flaws in medical devices and hospital equipment that officials fear could be exploited by hackers, a senior official at the agency told Reuters.

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

October 22, 2014 by MassDevice

Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

Covidien, Medtronic shares jump on affirmation of $43B merger

October 22, 2014 by Brad Perriello

Shares of Medtronic and Covidien gain after Medtronic affirms its $43 billion acquisition plans, saying it now expects to close the deal for Covidien late this year or early in 2015.

Covidien, Medtronic shares jump on affirmation of $43B merger
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp